About this trial
This retrospective (between April 2020 and December 2023) then prospective (between January 2024 and August 2026), non-interventional cohort study has as its main objective to evaluate the clinical and therapeutic characteristics of patients aged 75 and over hospitalized in geriatrics for heart failure and also to evaluate the clinical characteristics and triggering factor(s) of acute heart failure.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients aged 75 and over Hospitalized in a geriatric ward with heart failure No oral opposition from patient
Disqualifiers
Patient under 75 years of age Patient not wishing to participate in the study Subject under guardianship/curatorship/supervision of justice
Trial population
Patients aged 75 and over hospitalized in geriatrics for heart failure
Trial design
Cohort
Other
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Evaluate the clinical and therapeutic characteristics of elderly patients hospitalized in geriatrics for heart failure
To Evaluate the clinical and therapeutic characteristics of elderly patients hospitalized in geriatrics for heart failure with 80% power and 5% alpha risk and expressed as a percentage.
Secondary outcomes
Factors associated with patients hospitalization or rehospitalization
Quantitative data will be described as mean ± standard deviation. Qualitative variables will be expressed as percentages Statistical differences (hospitalized and/or deceased vs. non-rehospitalized and/or non-deceased patients) will be assessed using the Mann-Whitney U-test and Student's t-test for non-parametric and parametric continuous variables, respectively. Discrete variables will be normally distributed, and by the Mann-Whitney test for those not normally distributed. Survival curves will be drawn to analyze mortality and hospitalizations. Evaluated using the χ2 or Fisher test. Differences between groups will be assessed by ANOVA for the variables
Locations
This trial is not recruiting at the moment. You can still explore other options: